Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John R. Zalcberg, Cesar Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean Yves Blay, Margaret Von Mehren, Patrick Sch€offski

Research output: Contribution to journalArticlepeer-review

Abstract

Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across KIT/PDGFRA mutation subgroups.

Original languageEnglish (US)
Pages (from-to)6333-6342
Number of pages10
JournalClinical Cancer Research
Volume27
Issue number23
DOIs
StatePublished - Dec 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study'. Together they form a unique fingerprint.

Cite this